{"id":388996,"date":"2024-12-30T00:00:00","date_gmt":"2024-12-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2024-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:32","modified_gmt":"2026-03-31T10:27:32","slug":"dlsfon0010-2024-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2024-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and neck. Although patients with locoregionally advanced SCCHN are generally prescribed chemotherapy-based regimens, targeted therapies are frequently prescribed to patients with recurrent or metastatic disease. The usual treatment algorithm starts with a PD-1 inhibitor (pembrolizumab [Keytruda]) for recurrent or metastatic disease, followed by an EGFR-targeting agent (cetuximab [Erbitux]) after progression. The expected approval of zanzalintinib (in combination with pembrolizumab) as a first-line treatment, along with the approval of petosemtamab (in combination with pembrolizumab), will significantly impact treatment in the recurrent and metastatic settings during the 2023-2033 forecast period. Buparlisib (in combination with paclitaxel), ficlatuzumab (in combination with cetuximab), and petosemtamab in later-line treatment will also contribute to this transformation. Finally, the approval of toripalimab is setting a new treatment paradigm for SCCHN. We anticipate strong adoption of toripalimab, alongside the immune checkpoint inhibitor penpulimab, whose approval we expect soon.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the anticipated evolution in the size of the drug-treatable SCCHN populations from 2023 to 2033, and how will it impact the landscape of available treatment options?<\/li>\n<li>What are the key current therapies for locoregionally advanced and recurrent or metastatic SCCHN, and what is their positioning?<\/li>\n<li>How will drugs in late-phase development for SCCHN gain market and patient share?<\/li>\n<li>What are the driving forces and limitations influencing the SCCHN therapy market, and how do experts foresee these factors evolving over the 10-year forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-388996","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388996\/revisions"}],"predecessor-version":[{"id":575845,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388996\/revisions\/575845"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=388996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}